Medical sensor specialist Lifecare ASA (OSE:LIFE) has submitted an application for regulatory approval to begin its first human clinical trial for a wireless continuous glucose monitoring (CGM) implant, the company announced on Tuesday.
The filing follows a finalised design phase, supporting trial preparations and continued progress in manufacturing development.
This milestone aligns with Lifecare's clinical and commercial roadmap, marking a significant step toward CE-mark certification.
Regulatory approval is anticipated in the third quarter of 2025, with trial completion expected by early fourth quarter, subject to timely authorisation.
Lifecare aims to begin its pivotal CE-mark clinical trial later this year, targeting completion in 2026.
Commercial launch of the CGM implant for human use is planned for 2027.
Revalesio reports further analysis from Phase 2 RNS60 trial for acute ischemic stroke treatment
AnnJi reports positive Phase 1/2a results in Spinal and Bulbar Muscular Atrophy trial
Sarepta receives UK approval to continue dosing in ELEVIDYS ENVISION study
MSD expands clinical development of Orion's opevesostat to include women's cancers
Promontory Therapeutics reports successful FDA meeting after Phase 2 study of PT-112
Trevi Therapeutics reports additional results from Phase 2a RIVER trial of Haduvio
Accropeutics reports positive data from Phase 2 psoriasis treatment trial
NextCell Pharma partners with Fujifilm Irvine Scientific to deliver integrated MSC solutions
Lifecare files for first human trial of glucose monitoring implant, targeting CE-mark
EXACT Therapeutics reports strong Phase 1 results for ACTIVATE trial in colorectal liver metastases
Shanton to present data from gout study at EULAR 2025 Congress
UCB and Domino Data Lab partner to modernise Statistical Computing Environment for life sciences